Category Cancer Types

23
Aug

Researchers Discover Molecule That Drives Aggressive Breast Cancer

Recent studies by researchers at Thomas Jefferson University’s Kimmel Cancer Center have shown a gene known to coordinate initial development of the eye (EYA1) is a powerful breast tumor promoter in mice. The gene EYA1 was also shown to be overexpressed in a genetic breast cancer subtype called luminal B. The scientists found that excess …

23
Aug

KCC Ranked as One of Best Cancer Hospitals in US

Men’s Health magazine recently ranked the Kimmel Cancer Center at Jefferson among the best in the nation, calling out its success in treating prostate cancer, a leading cancer in men. The American Cancer Society estimates there will be more than 1.5 million new cancer diagnoses in 2013. Jefferson scientist, Matthew Schiewer, Ph.D., recently received the Prostate Cancer Benjamin …

15
Jul

Ladies of Port Richmond Featured in Inquirer

Mary Louise Leuters is a two-time breast cancer survivor and president of the Ladies of Port Richmond, a local group of breast cancer survivors who have raised over $400,000 for breast cancer research in the last nine years.Nearly 300,000 American women will be diagnosed with breast cancer this year, and 40,000 will die from it, …

3
Jul

Keatley Foundation Donation

The Keatley Foundation made a generous $10,000 donation to the Kimmel Cancer Center.   Events like their second annual Beef and Beer contributed to this generous donation. The Keatley Foundation was created by Bob Lyons during his treatment at Jefferson Hospital. The foundation name comes from the street name where Bob lives. According to Bob, That …

18
Jun

KCC Investigator wins Prostate Cancer Foundation Benjamin Franklin Young Investigator Award

Matthew Schiewer, PhD, a postdoctoral fellow in Dr. Karen Knudsen’s lab in the Department of Cancer Biology, is the recent recipient of a Prostate Cancer Foundation Young Investigator Award. Dr. Schiewer’s investigations will focus on the role of PARP-1 in DNA damage repair and the inhibition of PARP with specific medications as a potential therapy …

8
May

Jefferson Post-Doc Receives National Cancer Center Fellowship

Edward Hartsough, Ph.D. received a post-doctoral fellowship from the National Cancer Center Organization ( http://www.nationalcancercenter.org/ ).  The fellowship grant is entitled “Next-Generation RAF Inhibitors in V600E BRAF Melanoma.”  Dr. Hartsough works in Dr. Andrew Aplin’s lab at the Kimmel Cancer Center. The National Cancer Center was founded by Dr. J. Ernest Ayre in 1953 as …

12
Feb

Massimo Cristofanilli, M.D., Appointed Director of the Jefferson Breast Care Center

Massimo Cristofanilli, M.D., FACP, an internationally renowned breast cancer researcher and clinician, has been appointed Director of the Jefferson Breast Care Center at the Kimmel Cancer Center (KCC) and Thomas Jefferson University and Hospitals. With more than 25 years of clinical, basic science and educational experience, Dr. Cristofanilli will also serve as Deputy Director of …

12
Feb

Jefferson Opens Calorie Restriction Trial for Early Stage Breast Cancer Patients on Radiation Therapy

Jefferson’s Kimmel Cancer Center will begin a first-of-its-kind clinical trial that uses calorie restriction to help treat early stage breast cancer patients undergoing radiation therapy. Evidence suggests that reducing patients’ calorie intake could help shrink tumors and improve survival because it enhances the effectiveness of radiation therapy, the team explains in a recent review published …

12
Feb

Jefferson Radiation Oncology Resident Looks to Improve Prostate Cancer Outcomes in Ghana

A new study published in January in the journal BMC Cancer, led by Kosj Yamoah, M.D., Ph.D., a resident in the Department of Radiation Oncology at Thomas Jefferson University and Hospital, takes aim at the issue by investigating prostate cancer diagnoses and treatment delivery in black men living in the West African region, in order …

12
Feb

Phone and Mailed Interventions Significantly Increase Colorectal Cancer Screening Rates

A mailing or phone call to help patients get screened for colorectal cancer significantly increases their chances of actually getting tested, according to a study published in the January issue of Cancer Epidemiology, Biomarkers and Prevention by researchers at the Kimmel Cancer Center at Jefferson. The research team, led by Ronald E. Myers, Ph.D., Professor …

12
Feb

Radiation Oncology Services Expanding at Riddle Hospital

Jefferson Radiation Oncology at Riddle Memorial Hospital is pleased to announce that the expansion of Radiation Oncology services has begun. In the next few months, the Department will begin installing a new True –Beam linear accelerator, Brachytherapy High Dose Rate machine and a CT scanner. Construction is expected to be completed by December 2013. The acquisition of this …

9
Jan

Bench to Bedside: How to Fast Track Targeted Cancer Drugs with Radiation into the Clinic

Researchers from the translational research program of the National Cancer Institute and the Radiation Therapy Oncology Therapy Group have developed new guidelines to help fast track the clinical development of targeted cancer drugs in combination with radiation therapy. The suggested strategic guidelines, published in the Journal of the National Cancer Institute in a recent commentary …

8
Jan

More Designated Time Equals More Published Research for Radiation Oncology Residents

What helps radiation oncologist residents publish more academic research? Giving them more time to do it, physicians in the Department of Radiation Oncology at Thomas Jefferson University Hospital conclude in a study published recently in the Journal of American College of Radiology. Based on results from a web-based survey completed by 97 radiation oncologists and …

21
Dec

Game changing diagnostic & prognostic prostate cancer genetic tests revealed by KCC researchers

Researchers at the Kimmel Cancer Center at Jefferson (KCC) have developed potentially game-changing diagnostic and prognostic genetic tests shown to better predict prostate cancer survival outcomes and distinguish clinically-relevant cancers. The team, led by Richard G. Pestell, M.D., Ph.D., Director of the KCC and the Chair of the Department of Cancer Biology at Thomas Jefferson …

21
Dec

KCC researchers discover new pathways that drive metastatic prostate cancer

Elevated levels of Cyclin D1b could function as a novel biomarker of lethal metastatic disease in prostate cancer patients, according to a pre-clinical study published ahead of print on December 21 in the Journal of Clinical Investigation by researchers at the Kimmel Cancer Center at Jefferson. The group, headed by Karen E. Knudsen, Ph.D., Professor …

23
Oct

Dr. Renato Iozzo appointed as Editor-In-Chief of Matrix Biology

Renato Iozzo, M.D., Ph.D.,  a Professor of Pathology, Anatomy and Cell Biology at Thomas Jefferson University, has recently been appointed as Editor-in-Chief of the journal Matrix Biology beginning January 2013. This flagship journal is published by Elsevier and is affiliated with both the International Society for Matrix Biology and the American Society for Matrix Biology. …

22
Oct

NCI Awards ‘Provocative Questions’ Grant to Thomas Jefferson University Researcher Scott Waldman

Scott Waldman, M.D., Ph.D., chairman of the Department of Pharmacology and Experimental Therapeutics at Thomas Jefferson University, has been awarded one of the prestigious “Provocative Questions”  grants from the National Cancer Institute (NCI) , as part of the Institute’s ambitious program to tackle the “important but not obvious” questions in cancer to ensure no stone …

16
Oct

Stat5 Predicts Outcomes for Prostate Cancer Patients after Radical Prostatectomy

Men who had high levels of the activated Stat5 protein in their prostate cancer after a radical prostatectomy were more likely to have a recurrence or die from the disease compared to men who had little to no presence of the growth protein, according to a recent study published in Human Pathology by Jefferson’s Kimmel …

9
Oct

Doubling up on Advanced Prostate Cancer with PARP Inhibitors

A newly discovered function of PARP-1 could be the key to more effective therapeutics to treat advanced prostate cancer patients, a recent preclinical study published in Cancer Discovery by Jefferson’s Kimmel Cancer Center researchers suggests. The team, led by Karen E. Knudsen, Ph.D., Professor in the Departments of Cancer Biology, Urology, & Radiation Oncology at …

20
Sep

Tissue around tumor holds key to fighting triple negative breast cancer

A natural substance found in the surrounding tissue of a tumor may be a promising weapon to stop triple negative breast cancer from metastasizing. A preclinical study published in PLOS ONE September 19 by Thomas Jefferson University researchers found that decorin, a well-studied protein known to help halt tumor growth, induces a series of tumor …

Page 3 of 11